Cannabis Intelligence Report
Legislation updates, research breakthroughs, industry analysis, and cultural shifts — curated by our expert team.
Federal Rescheduling Advances: What Schedule III Means for Cannabis Research
The DEA's proposal to move cannabis from Schedule I to Schedule III marks the most significant federal policy shift in decades. We break down what it means for researchers, dispensaries, and consumers.
Stanford Study Links Specific Terpene Combinations to Anxiety Reduction
A landmark double-blind study from Stanford's Department of Psychiatry identifies linalool-limonene combinations as significantly more effective than isolated CBD for generalized anxiety.
Cannabis Market Reaches $50B Milestone as Legalization Spreads to 38 States
New market data confirms the US cannabis industry has crossed the $50 billion annual revenue threshold, with projections suggesting $80B by 2028.
The Rise of Cannabis Sommeliers: How Connoisseur Culture Is Reshaping the Industry
From terpene tastings to strain pairing menus, a new class of cannabis professionals is elevating the consumption experience to fine dining territory.
New Clinical Trial Shows THC/CBD Combination Reduces Opioid Use by 40% in Chronic Pain Patients
A multi-center trial published in JAMA Pain Medicine demonstrates significant opioid-sparing effects when patients use a 1:1 THC:CBD protocol alongside standard pain management.
THCV Shows Promise as Metabolic Syndrome Treatment in Phase II Trial
Preliminary results from a Phase II clinical trial suggest tetrahydrocannabivarin (THCV) may improve insulin sensitivity and reduce waist circumference in metabolic syndrome patients.
Germany's Cannabis Legalization: Six-Month Report Card
Six months after Germany became the first major EU nation to legalize recreational cannabis, we examine the data on consumption patterns, black market impact, and public health outcomes.
Big Pharma Enters the Cannabis Space: What It Means for the Industry
Three major pharmaceutical companies have announced cannabis R&D divisions in Q2 2026. Industry veterans weigh in on whether this is a threat or validation.
Legal Status Tracker
14
Recreational
2
Medical